Smectite other active pharmaceutical ingredients

Luye Pharma Group, established in 1994 in China and listed on the Hong Kong Stock Exchange, develops, produces, and markets innovative pharmaceutical products focused on oncology, cardiovascular disease, and alimentary tract/metabolism, with central nervous system disorders emerging as a growing focus area. The company pioneered China's first liposome industrialization breakthrough and developed proprietary continuous dynamic preparation technology for microspheres, leading internationally in long-acting microsphere treatments for neurodegenerative diseases, alongside internationally marketed Paclitaxel liposome formulations. Through acquisitions — including Nanjing Kanghai and Cisco Pharmaceutical (2007), the transdermal drug-delivery business of Swiss group Acino (2016), and rights to AstraZeneca's Seroquel and its slow-release tablets across 51 countries (2018) — Luye has expanded from its Yantai, Shandong origins into mainstream European and US markets, with production lines passing EU GMP inspection in 2013. Offering CRO services and backed by an experienced, internationally certified R&D team, the company distributes its rich portfolio of finished dosage forms, APIs, and bio products across Central/South America, Eastern Europe, Asia, the Middle East, North America, and Western Europe.